Bruce D Cheson

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi Role of functional imaging in the management of lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 29:1844-54. 2011
  2. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
  3. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
  4. ncbi The International Harmonization Project for response criteria in lymphoma clinical trials
    Bruce D Cheson
    Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Hematol Oncol Clin North Am 21:841-54. 2007
  5. ncbi Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    Bruce D Cheson
    Division of Hematology-Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    N Engl J Med 359:613-26. 2008
  6. ncbi A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Cancer 118:3128-34. 2012
  7. ncbi Monoclonal antibody therapy for B-cell malignancies
    Bruce D Cheson
    Department of Hematology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 33:S2-14. 2006
  8. ncbi Bendamustine: rebirth of an old drug
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 27:1492-501. 2009
  9. ncbi Staging and evaluation of the patient with lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Hematol Oncol Clin North Am 22:825-37, vii-viii. 2008
  10. ncbi Managing malignancy-associated hyperuricemia with rasburicase
    Bruce D Cheson
    Georgetown University, Lombardi Comprehensive Cancer, Center, Washington, DC 20007, USA
    J Support Oncol 3:117-24. 2005

Detail Information

Publications80

  1. ncbi Role of functional imaging in the management of lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 29:1844-54. 2011
    ..FDG-PET has the potential to improve lymphoma patient management; however, its usefulness will likely vary by histology, stage, therapy, and clinical setting...
  2. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  3. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  4. ncbi The International Harmonization Project for response criteria in lymphoma clinical trials
    Bruce D Cheson
    Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Hematol Oncol Clin North Am 21:841-54. 2007
    ..Modifications of these recommendations are expected as new information and improved technologies become available...
  5. ncbi Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    Bruce D Cheson
    Division of Hematology-Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    N Engl J Med 359:613-26. 2008
  6. ncbi A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Cancer 118:3128-34. 2012
    ..YM155 is a survivin suppressant with activity against DLBCL in a phase I trial. This phase II study was conducted to better characterize the toxicity and efficacy of this small molecule in patients with refractory DLBCL...
  7. ncbi Monoclonal antibody therapy for B-cell malignancies
    Bruce D Cheson
    Department of Hematology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 33:S2-14. 2006
    ..New treatment regimens, including combinations of monoclonal antibodies, could enhance complete response rates and prolong progression-free survival, perhaps eventually improving our ability to cure patients with lymphoid malignancies...
  8. ncbi Bendamustine: rebirth of an old drug
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 27:1492-501. 2009
    ..However, the availability of bendamustine provides another effective treatment option for patients with lymphoid malignancies...
  9. ncbi Staging and evaluation of the patient with lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Hematol Oncol Clin North Am 22:825-37, vii-viii. 2008
    ..This article addresses the advances in staging and evaluation of patients who have lymphoma, specifically examining the use of positron emission tomography...
  10. ncbi Managing malignancy-associated hyperuricemia with rasburicase
    Bruce D Cheson
    Georgetown University, Lombardi Comprehensive Cancer, Center, Washington, DC 20007, USA
    J Support Oncol 3:117-24. 2005
    ..Current and future trials will evaluate alternate doses and schedules of rasburicase to maintain its efficacy while reducing its cost...
  11. ncbi New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road Northwest, Washington, DC 20007, USA
    Radiol Clin North Am 46:213-23, vii. 2008
    ....
  12. ncbi Overcoming mechanisms of RECISTance in lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Washington, DC 20007, USA
    Leuk Lymphoma 48:447-8. 2007
  13. ncbi Monoclonal antibody therapy of chronic lymphocytic leukemia
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC, USA
    Cancer Immunol Immunother 55:188-96. 2006
    ..The rational development of combinations of these promising approaches may eliminate the need for chemotherapy, leading to safer and more effective approaches for patients with CLL...
  14. ncbi The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    BioDrugs 19:309-22. 2005
    ....
  15. ncbi Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 34:S3-7. 2007
    ....
  16. ncbi The cancer and leukemia group B lymphoma committee
    Bruce D Cheson
    Georgetown University Hospital, Washington, District of Columbia and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 12:3572s-5s. 2006
    ..The Cancer and Leukemia Group B (CALGB) Lymphoma Committee highlight below clinical trials that have resulted in improved patient outcome for the more frequent lymphoma subtypes...
  17. ncbi Novel therapies for peripheral T-cell non-Hodgkin's lymphomas
    Bruce D Cheson
    Georgetown University Hospital, 3800 Reservoir Road, N W, Washington, DC 20007, USA
    Curr Opin Hematol 16:299-305. 2009
    ..To review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma...
  18. ncbi Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    J Clin Oncol 28:3525-30. 2010
    ..Ofatumumab offers another effective agent with which to improve the outcome of patients with B-cell malignancies...
  19. ncbi Targeted treatment and new agents in follicular lymphoma
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, 3800 Reservoir Road N W, Washington, DC 20007, USA
    Int J Hematol 92:5-11. 2010
    ....
  20. ncbi Is BEACOPP better than ABVD?
    Bruce D Cheson
    Georgetown University Hospital, 3800 Reservoir Road N W, Washington, DC 20007, USA
    Curr Hematol Malig Rep 2:161-6. 2007
    ..The answer to whether escalated BEACOPP is superior to ABVD will require the results of an ongoing randomized trial...
  21. ncbi New agents in follicular lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, United States
    Best Pract Res Clin Haematol 24:305-12. 2011
    ....
  22. ncbi Monoclonal antibody therapy of chronic lymphocytic leukaemia
    Bruce D Cheson
    Divison of Hematology Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Best Pract Res Clin Haematol 23:133-43. 2010
    ..Through rational combinations with chemotherapy and other biologic agents, the outcome for patients with CLL will further improve...
  23. ncbi Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Clin Lymphoma Myeloma Leuk 10:21-7. 2010
    ..This report, representing the conclusions of that meeting, should provide guidance for the clinician until definitive dose-finding studies have been conducted...
  24. ncbi Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Clin Adv Hematol Oncol 7:263-71. 2009
    ..This review discusses the relevance of TLS to CLL treatment and provides guidelines for diagnosis, prevention, and treatment of TLS in patients being treated for CLL...
  25. ncbi Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  26. ncbi Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road N W, Washington, DC, USA
    Clin Lymphoma Myeloma Leuk 10:452-7. 2010
    ..Bendamustine, a mechlorethamine alkylator with novel mechanisms of action, is approved in the United States for rituximab-refractory indolent B-cell NHL...
  27. ncbi Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 48:1313-9. 2007
    ..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL...
  28. ncbi Emerging treatments for indolent lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Clin Adv Hematol Oncol 5:1-9; quiz 11-2. 2007
    ..Other emerging therapeutics include new chemotherapeutics, small-molecule and monoclonal antibodies, radioimmunotherapy, apoptosis-inducing agents, and immunomodulators...
  29. ncbi Radioimmunotherapy of non-Hodgkin's lymphomas
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd, N W, Washington, DC 20007, USA
    Curr Drug Targets 7:1293-300. 2006
    ..Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL...
  30. ncbi Novel therapies for chronic lymphocytic leukemia
    Blanche H Mavromatis
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Blood Rev 18:137-48. 2004
    ..The mechanism of action of the new drugs and their role in CLL, as well as the emergence of new prognostic markers are discussed...
  31. ncbi Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma
    Jamie L Koprivnikar
    Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Future Oncol 8:359-71. 2012
    ..Bortezomib in combination with R-CHOP has also been suggested to improve response in certain molecular subgroups of diffuse large B-cell lymphoma. The role of bortezomib in follicular and marginal zone lymphomas remains less clear...
  32. ncbi Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma
    Chaitra Ujjani
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    Expert Rev Anticancer Ther 10:1353-65. 2010
    ..Here, we will discuss in the detail the molecular properties, clinical efficacy and safety profile of bendamustine...
  33. ncbi Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer 107:2817-25. 2006
    ..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)...
  34. ncbi Monoclonal antibodies in advanced B-cell lymphomas
    Chaitra Ujjani
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Oncology (Williston Park) 24:156-66. 2010
    ..The eventual goal of targeted therapies is to individualize treatment to increase response and survival, while reducing treatment-related toxicity...
  35. ncbi Monoclonal antibody therapy of chronic lymphocytic leukemia
    Blanche Mavromatis
    Department of Hematology/Oncology, Lombardi Cancer Center, Georgetown University Hospital, 3800 Reservoir Rd, N.W, Washington, DC, USA
    J Clin Oncol 21:1874-81. 2003
    ..It is hoped that the rational development of combinations of the various promising antibodies with chemotherapy and each other will lead to more effective approaches for patients with CLL...
  36. ncbi Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement
    Ekatherine Asatiani
    Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Am J Hematol 77:144-6. 2004
    ..0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown...
  37. ncbi What is new in lymphoma?
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    CA Cancer J Clin 54:260-72. 2004
    ....
  38. ncbi Mantle cell lymphoma: clinicopathologic features and treatments
    John Kauh
    Lombardi Cancer Center, Georgetown University Hospital, Washington, DC, USA
    Oncology (Williston Park) 17:879-91, 896; discussion 896-8. 2003
    ....
  39. ncbi Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    ..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
  40. ncbi Pre- and post-treatment evaluation of non-Hodgkin's lymphoma
    Blanche H Mavromatis
    Georgetown University Medical Center, Washington, DC, USA
    Best Pract Res Clin Haematol 15:429-47. 2002
    ....
  41. ncbi Radioimmunotherapy of non-Hodgkin lymphomas
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Cancer Center, Washington, DC 20007, USA
    Blood 101:391-8. 2003
    ..Ongoing clinical trials are attempting to better characterize the role of these promising agents...
  42. ncbi Implementing an expressive writing study in a cancer clinic
    Nancy P Morgan
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Oncologist 13:196-204. 2008
    ..These preliminary findings indicate that a single, brief writing exercise is related to cancer patients' reports of improved quality of life...
  43. ncbi Oral fludarabine: a viewpoint by Bruce D. Cheson
    Bruce D Cheson
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Drugs 63:2325. 2003
  44. ncbi Letter from the editor
    Bruce D Cheson
    Georgetown University School of Medicine, Washington, DC 20052, USA
    Clin Adv Hematol Oncol 3:5. 2005
  45. ncbi Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA
    Clin Adv Hematol Oncol 9:1-11. 2011
    ..Proper reporting of adverse events is critical, as are proper clinical trial design and long-term follow-up...
  46. ncbi The current status and future impact of targeted therapies in non-Hodgkin lymphoma
    Chaitra Ujjani
    Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    Expert Rev Hematol 6:191-203. 2013
    ....
  47. ncbi Letter from the editor
    Bruce D Cheson
    Georgetown University School of Medicine, Washington, DC 20052, USA
    Clin Adv Hematol Oncol 2:139. 2004
  48. ncbi CLL response criteria
    Bruce D Cheson
    Hematology, Georgetown University Hospital, Washington, DC, USA
    Clin Adv Hematol Oncol 4:4-5; discussion 10; suppl 12. 2006
  49. ncbi Histiocytic sarcoma transdifferentiated from follicular lymphoma presenting as a cutaneous tumor
    Weifen Zeng
    Department of Pathology, Georgetown University Hospital, Washington, DC, USA
    J Cutan Pathol 38:999-1003. 2011
    ..Lineage transdifferentiation can occur in mature lymphoid neoplasms and awareness of this phenomenon and appropriate workup is crucial for correct diagnosis, as different treatment protocols and prognosis may vary...
  50. ncbi Serving interests in hematologic malignancies in the journal of clinical oncology
    Bruce D Cheson
    Georgetown University, Washington, DC, USA
    J Clin Oncol 23:3666-7. 2005
  51. ncbi The sarcoid-lymphoma syndrome
    Trishna Goswami
    Georgetown University Hospital, Washington, DC 20007, USA
    Clin Lymphoma Myeloma Leuk 10:241-7. 2010
    ..As both entities are fluorine-18 fluorodeoxyglucose avid, histologic verification and clinical acumen are needed to avoid misdiagnosis before initiating therapy...
  52. ncbi Hematologic malignancies: new developments and future treatments
    Bruce D Cheson
    Clinical Investigations Branch, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 29:33-45. 2002
    ..Future therapeutic strategies should involve rational combinations of new chemotherapy drugs, biologic agents, and antisense compounds to increase the cure rate in patients with lymphoma...
  53. ncbi Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology
    Julie Gralow
    American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 26:313-25. 2008
    ..I hope you find it useful. Sincerely, Nancy E. Davidson, MD President American Society of Clinical Oncology...
  54. ncbi CHOP plus rituximab--balancing facts and opinion
    Bruce D Cheson
    N Engl J Med 346:280-2. 2002
  55. ncbi Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005
    ....
  56. ncbi Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    K Sue Robinson
    QE II Health Sciences Centre, Halifax, Nova Scotia, Canada
    J Clin Oncol 26:4473-9. 2008
    ..This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab...
  57. ncbi Bendamustine in the treatment of hematologic malignancies. Introduction
    Volker Diehl
    Department of Internal Medicine, University Hospital, Cologne, Germany
    Semin Oncol 29:1-3. 2002
  58. ncbi Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
    ....
  59. ncbi Recent developments in the treatment of CLL
    Bruce D Cheson
    Clin Adv Hematol Oncol 6:6-8; quiz 10-2. 2008
  60. ncbi Rituximab: clinical development and future directions
    Bruce D Cheson
    National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 2:97-110. 2002
    ..The future promise of this antibody is a foundation on which to develop new strategies to increase the cure of patients with lymphoid malignancies...
  61. ncbi The role of FDG-PET scans in patients with lymphoma
    Pamela Seam
    National Cancer Institute, Bethesda, MD, USA
    Blood 110:3507-16. 2007
    ..Recent attempts to standardize PET in clinical trials and incorporation of this technology into uniformly adopted response criteria will hopefully lead to improved outcome for patients with lymphoma...
  62. ncbi Role of positron emission tomography in lymphoma
    Malik E Juweid
    J Clin Oncol 23:4577-80. 2005
  63. ncbi The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
    ..The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes...
  64. ncbi Positron-emission tomography and assessment of cancer therapy
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    N Engl J Med 354:496-507. 2006
  65. ncbi Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA
    J Clin Oncol 26:204-10. 2008
    ..This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab...
  66. ncbi Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    Br J Haematol 140:313-9. 2008
    ..Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide...
  67. ncbi Lenalidomide for the treatment of B-cell malignancies
    Asher A Chanan-Khan
    Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 26:1544-52. 2008
    ..This review summarizes the data from various clinical investigations and highlights the impact of lenalidomide in the management of patients with B-cell malignancies...
  68. ncbi Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
    ..The activity in Burkitt's lymphoma should be investigated further...
  69. ncbi Clinical trials referral resource. Current clinical trials in non-Hodgkin's lymphoma
    Bruce D Cheson
    National Cancer Institute, USA
    Oncology (Williston Park) 16:762-3, 766. 2002
  70. ncbi Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra)
    John J Wright
    National Cancer Institute, USA
    Oncology (Williston Park) 16:930-1, 935-7. 2002
  71. ncbi An oncoethical issue
    Bruce D Cheson
    Clin Adv Hematol Oncol 4:241. 2006
  72. ncbi Letter from the editor
    Bruce D Cheson
    Clin Adv Hematol Oncol 2:695. 2004
  73. ncbi Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:97-103. 2007
    ..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule...
  74. ncbi The Peoria Principle
    Bruce D Cheson
    Clin Adv Hematol Oncol 2:627. 2004
  75. ncbi Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia
    Upendra P Hegde
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:2260-2. 2002
    ..These results suggest rituximab can rapidly reverse refractory fludarabine-associated ITP...
  76. ncbi Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams
    Bruce D Cheson
    J Clin Oncol 23:6283-4. 2005
  77. ncbi Although many of the items are natural products, we do not know what harm they might cause in the often excessive quantities that are recommended
    Bruce D Cheson
    Clin Adv Hematol Oncol 5:499. 2007
  78. ncbi Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer
    Malcolm A Smith
    National Cancer Institute, USA
    Oncology (Williston Park) 16:328, 331-3, 338 passim. 2002
  79. ncbi CT/PET scan
    Bruce D Cheson
    Clin Adv Hematol Oncol 3:483. 2005
  80. ncbi Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
    Wyndham H Wilson
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 99:2685-93. 2002
    ..Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens. Dynamic dose adjustment may overcome inadequate drug concentrations, particularly in younger patients, and compensate for increased drug clearance over time...